BACLOFEN tablet

País: Estats Units

Idioma: anglès

Font: NLM (National Library of Medicine)

ingredients actius:

BACLOFEN (UNII: H789N3FKE8) (BACLOFEN - UNII:H789N3FKE8)

Disponible des:

Unit Dose Services

Designació comuna internacional (DCI):

BACLOFEN

Composición:

BACLOFEN 20 mg

Vía de administración:

ORAL

tipo de receta:

PRESCRIPTION DRUG

indicaciones terapéuticas:

Baclofen tablets USP are useful for the alleviation of signs and symptoms of spasticity resulting from multiple sclerosis, particularly for the relief of flexor spasms and concomitant pain, clonus, and muscular rigidity. Patients should have reversible spasticity so that baclofen treatment will aid in restoring residual function. Baclofen tablets USP may also be of some value in patients with spinal cord injuries and other spinal cord diseases. Baclofen tablets USP are not indicated in the treatment of skeletal muscle spasm resulting from rheumatic disorders. The efficacy of baclofen in stroke, cerebral palsy, and Parkinson’s disease has not been established and, therefore, it is not recommended for these conditions. Hypersensitivity to baclofen.

Resumen del producto:

Product: 50436-9023 NDC: 50436-9023-1 30 TABLET in a BOTTLE NDC: 50436-9023-2 60 TABLET in a BOTTLE NDC: 50436-9023-3 90 TABLET in a BOTTLE

Estat d'Autorització:

Abbreviated New Drug Application

Fitxa tècnica

BACLOFEN- BACLOFEN TABLET
UNIT DOSE SERVICES
----------
BACLOFEN TABLETS USP
4096
4097
RX ONLY
DESCRIPTION
Baclofen, USP is a muscle relaxant and antispastic.
Its chemical name is 4-amino-3-(4-chlorophenyl)-butanoic acid. The
structural formula is:
C
H ClNO M.W. 213.66
Baclofen, USP is a white to off-white odorless or practically odorless
crystalline powder. It is slightly
soluble in water, very slightly soluble in methanol and insoluble in
chloroform.
Each tablet, for oral administration, contains 10 mg or 20 mg
baclofen, USP. In addition, each tablet
contains the following inactive ingredients: anhydrous lactose,
colloidal silicon dioxide, dibasic
calcium phosphate dihydrate, magnesium stearate, microcrystalline
cellulose and sodium starch
glycolate.
CLINICAL PHARMACOLOGY
The precise mechanism of action of baclofen is not fully known.
Baclofen is capable of inhibiting both
monosynaptic and polysynaptic reflexes at the spinal level, possibly
by hyperpolarization of afferent
terminals, although actions at supraspinal sites may also occur and
contribute to its clinical effect.
Although baclofen is an analog of the putative inhibitory
neurotransmitter gamma-aminobutyric acid
(GABA), there is no conclusive evidence that actions on GABA systems
are involved in the production
of its clinical effects. In studies with animals baclofen has been
shown to have general CNS depressant
properties as indicated by the production of sedation with tolerance,
somnolence, ataxia, and respiratory
and cardiovascular depression. Baclofen is rapidly and extensively
absorbed and eliminated. Absorption
may be dose-dependent, being reduced with increasing doses. Baclofen
is excreted primarily by the
kidney in unchanged form and there is relatively large intersubject
variation in absorption and/or
elimination.
INDICATIONS AND USAGE
10
12
2
Baclofen tablets USP are useful for the alleviation of signs and
symptoms of spasticity resulting from
multiple sclerosis, particularly for the relief of flexor spasms and
concomitant pain, clonus, and
m